
Drug-delivery failures — not flawed science — are the hidden driver of late-stage trial failures.

Dr. Remo Moomiaie-Qajar is a trained surgeon from Yale University and a seasoned life science entrepreneur with over 17 years of experience building, investing in, and scaling biotechnology startups. He founded the company in 2018, originally spun out of UC San Diego as Cytonus, and recently orchestrated its strategic rebrand to Axiom Bioscience, pivoting the company from a single-asset developer into a high-value, multi-platform biotechnology leader.

Drug-delivery failures — not flawed science — are the hidden driver of late-stage trial failures.